Other Liver Disease — Total revenues
Gilead Sciences Other Liver Disease — Total revenues decreased by 59.4% to $114.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 29.2%, from $161.00M to $114.00M. Over 3 years (FY 2022 to FY 2025), Other Liver Disease — Total revenues shows an upward trend with a 27.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful commercialization, market penetration, or expansion of the secondary liver disease product portfolio, while a decrease may signal market saturation, competitive pressure, or product lifecycle maturity.
Detailed definition
This metric represents the total gross revenue generated from the sale of pharmaceutical products specifically categoriz...
Peer comparison
Comparable to secondary therapeutic segment revenues in other large-cap biopharmaceutical companies, often evaluated against the growth rates of primary core franchises to assess portfolio diversification.
gild_segment_other_liver_disease_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $106.50M | $106.50M | $106.50M | $106.50M | $96.25M | $96.25M | $96.25M | $96.25M | $107.00M | $113.00M | $116.00M | $131.00M | $161.00M | $201.00M | $231.00M | $281.00M | $114.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -9.6% | +0.0% | +0.0% | +0.0% | +11.2% | +5.6% | +2.7% | +12.9% | +22.9% | +24.8% | +14.9% | +21.6% | -59.4% |
| YoY Change | — | — | — | — | -9.6% | -9.6% | -9.6% | -9.6% | +11.2% | +17.4% | +20.5% | +36.1% | +50.5% | +77.9% | +99.1% | +114.5% | -29.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's other liver disease — total revenues?
- Gilead Sciences (GILD) reported other liver disease — total revenues of $114.00M in Q1 2026.
- How has Gilead Sciences's other liver disease — total revenues changed year-over-year?
- Gilead Sciences's other liver disease — total revenues decreased by 29.2% year-over-year, from $161.00M to $114.00M.
- What is the long-term trend for Gilead Sciences's other liver disease — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's other liver disease — total revenues has grown at a 27.1% compound annual growth rate (CAGR), from $426.00M to $874.00M.
- What does other liver disease — total revenues mean?
- The total sales revenue generated from the company's secondary liver disease therapeutic product line.